Medicine
Tabloid 40 mg tablet
Tabloid 40 mg tablet is a prescription medicine containing Thioguanine for oral use, marketed by Waylis Therapeutics, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 15° to 25°C (59° to 77°F) in a dry place.
Key facts
- Active ingredient (INN)
- Thioguanine
- Brand
- Tabloid
- Strength
- 40 mg
- Dosage form
- Tablet
- Route
- Oral
- Packs
- 1 bottle
- Marketing authorisation holder
- Waylis Therapeutics
- Manufacturer
- Waylis Therapeutics
- Origin register
- US FDA, United States
- Storage
- Store at 15° to 25°C (59° to 77°F) in a dry place.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- L01BB03 Thioguanine
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 15 May 2023
- Identifiers
- RxCUI 105590, 198269DailyMed set ID 44b0c461-47fb-4106-ba11-6ed85530235cNDC 80725-630Application NDA012429
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 bottle in 1 carton / 25 tablet in 1 bottle | 80725-630-25 | Waylis Therapeutics | 15 May 2023 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 18 January 1966 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Thioguanine is an antimetabolite indicated for remission induction and remission consolidation treatment of acute nonlymphocytic leukemias. It is available as tablets for oral use. MedsAcross supplies Thioguanine for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about ThioguanineFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- TABLOID prescribing information (Waylis Therapeutics) · U.S. National Library of Medicine, DailyMed
Need Tabloid 40 mg tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.